DrugPatentWatch Database Preview

Details for Patent: 8,063,043

« Back to Dashboard

Which drugs does patent 8,063,043 protect, and when does it expire?

Patent 8,063,043 protects ODOMZO and is included in one NDA.

This patent has forty-seven patent family members in thirty-nine countries.

Summary for Patent: 8,063,043

Title:	Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(t- rifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
Abstract:	Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-- (trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide are prepared and characterized.
Inventor(s):	Bajwa; Joginder (Elmwood Park, NJ), de la Cruz; Marilyn (Matawan, NJ), Dodd; Stephanie Kay (Ayer, MA), Waykole; Liladhar Murlidhar (Succasunna, NJ), Wu; Raeann (Pine Brook, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/061,572
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 8,063,043

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharma Global	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 8,063,043

PCT Information
PCT Filed	September 15, 2009	PCT Application Number:	PCT/US2009/056918
PCT Publication Date:	March 25, 2010	PCT Publication Number:	WO2010/033481

International Family Members for US Patent 8,063,043

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	073591
Argentina	113778
Australia	2009293444
Canada	2736751